Effective novel therapies are required for nasopharyngeal cancers since nasopharyngeal patients are dysfunctional, and treatment remains a significant challenge. Here, a co-loading core-shell structured lipid-polymeric hybrids nanoparticles with gefitinib (GEF) and apatinib (APT) was established (GEF-APT-LPHNs). The LPHNs size, polydispersive index (PDI), zeta potential, and drug release properties were effectively investigated. The in vitro proliferation assay and cellular uptake displayed superior activity against the CNE2 and SUNE1 cells. Further, the morphological features of the CNE2 and SUNE1 cells were established by the dual staining method and nuclear damage staining strategy. Additionally, we evaluated an in vitro assay to assess the hemolytic properties of nanoparticles and discuss with the experiment the observed nanointerference. To prevent misleading effects from nanoparticles, we are proposing alternate approaches, debating the possible importance of nanoparticles in vitro systems.

鼻咽癌需要有效的新疗法，因为鼻咽患者功能障碍，治疗仍然是一个重大挑战。在这里，建立了与吉非替尼 (GEF) 和阿帕替尼 (APT) 共载的核壳结构脂质聚合物杂化纳米粒子 (GEF-APT-LPHNs)。有效地研究了 LPHN 的大小、多分散指数 (PDI)、zeta 电位和药物释放特性。体外增殖试验和细胞摄取对 CNE2 和 SUNE1 细胞显示出优异的活性。此外，通过双重染色方法和核损伤染色策略建立了 CNE2 和 SUNE1 细胞的形态特征。此外，我们还评估了一种体外测定，以评估纳米颗粒的溶血特性，并与实验讨论观察到的纳米干扰。